Cargando…

Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy

BACKGROUND: This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer and its impact on outcomes after pancreatoduodenectomy. METHODS: Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Flick, K. F., Al-Temimi, M. H., Maatman, T. K., Sublette, C. M., Swensson, J. K., Nakeeb, A., Ceppa, E. P., Nguyen, T. K., Schmidt, C. M., Zyromski, N. J., Tann, M. A., House, M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363010/
https://www.ncbi.nlm.nih.gov/pubmed/32671796
http://dx.doi.org/10.1007/s11605-020-04723-2
_version_ 1783559594864279552
author Flick, K. F.
Al-Temimi, M. H.
Maatman, T. K.
Sublette, C. M.
Swensson, J. K.
Nakeeb, A.
Ceppa, E. P.
Nguyen, T. K.
Schmidt, C. M.
Zyromski, N. J.
Tann, M. A.
House, M. G.
author_facet Flick, K. F.
Al-Temimi, M. H.
Maatman, T. K.
Sublette, C. M.
Swensson, J. K.
Nakeeb, A.
Ceppa, E. P.
Nguyen, T. K.
Schmidt, C. M.
Zyromski, N. J.
Tann, M. A.
House, M. G.
author_sort Flick, K. F.
collection PubMed
description BACKGROUND: This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer and its impact on outcomes after pancreatoduodenectomy. METHODS: Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic adenocarcinoma and underwent pancreatoduodenectomy from 2013 to 2018. Preoperative computed tomography scans were evaluated for the development of hepatic steatosis after neoadjuvant chemotherapy. Hypoattenuation included liver attenuation greater than or equal to 10 Hounsfield units less than tissue density of spleen on noncontrast computed tomography and greater than or equal to 20 Hounsfield units less on contrast-enhanced computed tomography. RESULTS: One hundred forty-nine patients received neoadjuvant chemotherapy for a median of 5 cycles (interquartile range (IQR), 4–6). FOLFIRINOX was the regimen in 78% of patients. Hepatic steatosis developed in 36 (24%) patients. The median time from neoadjuvant chemotherapy completion to pancreatoduodenectomy was 40 days (IQR, 29–51). Preoperative biliary stenting was performed in 126 (86%) patients. Neoadjuvant radiotherapy was delivered to 23 (15%) patients. Female gender, obesity, and prolonged exposure to chemotherapy were identified as risk factors for chemotherapy-associated hepatic steatosis. Compared with control patients without neoadjuvant chemotherapy-associated hepatic steatosis, patients developing steatosis had similar rates of postoperative pancreatic fistula (8% (control) vs. 4%, p = 0.3), delayed gastric emptying (8% vs. 14%, p = 0.4), and major morbidity (11% vs. 15%, p = 0.6). Ninety-day mortality was similar between groups (8% vs. 2%, p = 0.08). CONCLUSION: Hepatic steatosis developed in 24% of patients who received neoadjuvant chemotherapy but was not associated with increased morbidity or mortality after pancreatoduodenectomy.
format Online
Article
Text
id pubmed-7363010
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-73630102020-07-16 Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy Flick, K. F. Al-Temimi, M. H. Maatman, T. K. Sublette, C. M. Swensson, J. K. Nakeeb, A. Ceppa, E. P. Nguyen, T. K. Schmidt, C. M. Zyromski, N. J. Tann, M. A. House, M. G. J Gastrointest Surg SSAT Plenary Presentation BACKGROUND: This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer and its impact on outcomes after pancreatoduodenectomy. METHODS: Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic adenocarcinoma and underwent pancreatoduodenectomy from 2013 to 2018. Preoperative computed tomography scans were evaluated for the development of hepatic steatosis after neoadjuvant chemotherapy. Hypoattenuation included liver attenuation greater than or equal to 10 Hounsfield units less than tissue density of spleen on noncontrast computed tomography and greater than or equal to 20 Hounsfield units less on contrast-enhanced computed tomography. RESULTS: One hundred forty-nine patients received neoadjuvant chemotherapy for a median of 5 cycles (interquartile range (IQR), 4–6). FOLFIRINOX was the regimen in 78% of patients. Hepatic steatosis developed in 36 (24%) patients. The median time from neoadjuvant chemotherapy completion to pancreatoduodenectomy was 40 days (IQR, 29–51). Preoperative biliary stenting was performed in 126 (86%) patients. Neoadjuvant radiotherapy was delivered to 23 (15%) patients. Female gender, obesity, and prolonged exposure to chemotherapy were identified as risk factors for chemotherapy-associated hepatic steatosis. Compared with control patients without neoadjuvant chemotherapy-associated hepatic steatosis, patients developing steatosis had similar rates of postoperative pancreatic fistula (8% (control) vs. 4%, p = 0.3), delayed gastric emptying (8% vs. 14%, p = 0.4), and major morbidity (11% vs. 15%, p = 0.6). Ninety-day mortality was similar between groups (8% vs. 2%, p = 0.08). CONCLUSION: Hepatic steatosis developed in 24% of patients who received neoadjuvant chemotherapy but was not associated with increased morbidity or mortality after pancreatoduodenectomy. Springer US 2020-07-15 2020 /pmc/articles/PMC7363010/ /pubmed/32671796 http://dx.doi.org/10.1007/s11605-020-04723-2 Text en © The Society for Surgery of the Alimentary Tract 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle SSAT Plenary Presentation
Flick, K. F.
Al-Temimi, M. H.
Maatman, T. K.
Sublette, C. M.
Swensson, J. K.
Nakeeb, A.
Ceppa, E. P.
Nguyen, T. K.
Schmidt, C. M.
Zyromski, N. J.
Tann, M. A.
House, M. G.
Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
title Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
title_full Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
title_fullStr Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
title_full_unstemmed Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
title_short Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
title_sort hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer: incidence and implications for outcomes after pancreatoduodenectomy
topic SSAT Plenary Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363010/
https://www.ncbi.nlm.nih.gov/pubmed/32671796
http://dx.doi.org/10.1007/s11605-020-04723-2
work_keys_str_mv AT flickkf hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT altemimimh hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT maatmantk hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT sublettecm hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT swenssonjk hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT nakeeba hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT ceppaep hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT nguyentk hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT schmidtcm hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT zyromskinj hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT tannma hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy
AT housemg hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy